WILATE 500 UNIT / 5 ML
VON WILLEBRAND FACTOR (HUMAN) : 500 UNIT / 5 ML HUMAN PLASMA PROTEINS : 7.5 MG / 5 ML ANTIHEMOPHILIC FACTOR (HUMAN) : 500 UNIT / 5 ML · DIN 02286750 · OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
Health Canada status: MARKETED
What is WILATE?
WILATE 500 UNIT / 5 ML contains VON WILLEBRAND FACTOR (HUMAN) : 500 UNIT / 5 ML HUMAN PLASMA PROTEINS : 7.5 MG / 5 ML ANTIHEMOPHILIC FACTOR (HUMAN) : 500 UNIT / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02286750, held by OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Apr-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is WILATE used for?
wilate® is indicated for: Treatment and prophylaxis of bleeding in patients with hemophilia A (congenital or acquired FVIII deficiency) and for the prevention and treatment of bleeding in minor surgical procedures. wilate® is indicated for: Treatment and prophylaxis of spontaneous and trauma-induced bleeds in all types of VWD in adult and pediatric patients where use of DDAVP (1-deamino-8-D-arginine vasopressin/desmopressin) treatment is ineffective or contra-indicated. Prevention and treatment of bleeding during and after surgical procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02286750 |
|---|---|
| Brand name | WILATE |
| Generic / active ingredient | VON WILLEBRAND FACTOR (HUMAN) : 500 UNIT / 5 ML HUMAN PLASMA PROTEINS : 7.5 MG / 5 ML ANTIHEMOPHILIC FACTOR (HUMAN) : 500 UNIT / 5 ML |
| Manufacturer | OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H |
| Strength | 500 UNIT / 5 ML |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B02BD06 VON WILLEBRAND FACTOR AND COAG. FACT. VIII IN COMB |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Apr-2008 |
| Original market date | 2008-04-29 00:00:00 |
How is it stored and handled?
Warm the wilate® powder and solvent in the closed vials up to room temperature (maximum +37°C).
How is it supplied?
wilate® 500 in 5 mL, 1 package contains: 1 vial with powder, 1 vial with solvent (5 mL Water for Injection with 0.1% Polysorbate 80), 1 transfer device (Nextaro®) with integrated filter. wilate® 1000 in 10 mL, 1 package contains: 1 vial with powder, 1 vial with solvent (10 mL Water for Injection with 0.1% Polysorbate 80), 1 transfer device (Nextaro®) with integrated filter.
What can be used instead?
Other Canadian products sharing ATC code B02BD06 VON WILLEBRAND FACTOR AND COAG. FACT. VIII IN COMB. 5 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HUMATE-P | 1200 UNIT / 10 ML | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02261227 |
| HUMATE-P | 2400 UNIT / 15 ML | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02261235 |
| HUMATE-P | 600 UNIT / 5 ML | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02261219 |
| WILATE | 1000 UNIT / 10 ML | POWDER FOR SOLUTION | OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | MARKETED | DIN 02286769 |
| ALPHANATE | 1200 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | DIN 02475596 |
| ALPHANATE | 1500 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | DIN 02475618 |
| ALPHANATE | 2000 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | DIN 02475626 |
| ALPHANATE | 300 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | DIN 02475561 |
| ALPHANATE | 500 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | DIN 02475588 |
Who else supplies VON WILLEBRAND FACTOR AND COAG. FACT. VIII IN COMB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VON WILLEBRAND FACTOR AND COAG. FACT. VIII IN COMB appears in 11 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.